Page last updated: 2024-10-30

labetalol and Gestational Weight Gain

labetalol has been researched along with Gestational Weight Gain in 1 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Gestational Weight Gain: Increase in body weight of the mother during the course of her PREGNANCY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bastian, IN1
Antony, KM1

Other Studies

1 other study available for labetalol and Gestational Weight Gain

ArticleYear
Gestational weight gain among gravidae with hypertension receiving labetalol versus nifedipine.
    Pregnancy hypertension, 2022, Volume: 28

    Topics: Antihypertensive Agents; Blood Pressure; Female; Gestational Weight Gain; Humans; Hypertension; Labe

2022